ORAL Strategy, 216 or 18.8% received the Zostvax vaccine. Overall, 18 patients (1.6%) developed HZ (vaccinated=3; non-vaccinated=15). HZ IRs (95% CI) were 1.1 (0.3, 2.9), 2.3 (1.0, 4.6), and 1.7 (0.6, 3.7) for tofa monotherapy, tofa+MTX, & ADA+MTX, resp. https://t.co/SE5ANjRHB8